|PDL BioPharma, Inc.|
932 Southwood Boulevard
United States - Map
PDL BioPharma, Inc. engages in intellectual property asset management and patent portfolio and related assets investment activities. The company is involved in the humanization of monoclonal antibodies and the discovery of a new generation of targeted treatments for cancer and immunologic diseases, as well as other medical conditions. It offers Queen et al. patents that cover humanized antibodies, methods for humanizing antibodies, polynucleotide encoding in humanized antibodies, and methods of producing humanized antibodies. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.
|PDL BioPharma, Inc.’s ISS Governance QuickScore as of May 1, 2013 is 2. The pillar scores are Audit: 1; Board: 2; Shareholder Rights: 4; Compensation: 3.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. John P. McLaughlin J.D.,
Chief Exec. Officer, Pres, Director and Member of Litigation Committee
|Mr. Christopher L. Stone J.D.,
VP, Gen. Counsel and Sec.
|Mr. Danny J. Hart Jr., J.D.,
Deputy Gen. Counsel and Assistant Sec.
|Mr. Peter S. Garcia ,
Chief Financial Officer, Acting Chief Accounting Officer and VP
|Mr. Ami Knoefler ,
Investor Relations Professional
|Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|